about
Retinoid pathway and cancer therapeuticsFunction annotation of hepatic retinoid x receptor α based on genome-wide DNA binding and transcriptome profilingEffects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc Expression.Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a promising rexinoid lead compound for the development of cancer chemotherapeutic and chemoprMorphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer.Targeting truncated RXRα for cancer therapy.DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents.Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunizationDesign, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potentialSynthesis of 2-Aryl- and 2-Vinylpyrrolidines via Copper-Catalyzed Coupling of Styrenes and Dienes with Potassium β-Aminoethyl TrifluoroboratesPPAR agonists as therapeutics for CNS trauma and neurological diseasesBexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases.Suppressive effects of RXR agonist PA024 on adrenal CYP11B2 expression, aldosterone secretion and blood pressure.Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain.Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA.The IL-4/STAT6/PPARγ signaling axis is driving the expansion of the RXR heterodimer cistrome, providing complex ligand responsiveness in macrophages.Retinoid X receptor agonists inhibit hypertension-induced myocardial hypertrophy by modulating LKB1/AMPK/p70S6K signaling pathway.
P2860
Q34348117-96A16FA7-F784-47BE-B760-71604E6C48BEQ34482950-1086E6B5-8B0C-4E4C-9637-0C81B625DC7BQ35880635-1A927EE3-5B0F-411C-BDBC-5675A8D2055BQ36096584-815BB653-4E7B-4E72-A89D-055B4A0B6CFCQ36121396-0CEEEF86-6A40-468A-93F7-C196963063FCQ36398740-DEFE91FB-9757-4D8F-9682-5E1D23D56A4AQ36499766-6849A4BA-8FB6-4CA7-B3D1-938A6D934C0DQ36644869-FB986C44-9926-4F50-AD97-F282F377D41DQ36758674-27A84482-805F-4D3F-884A-D7B9FC7CC174Q36922223-2C6BB214-0FAE-4A3A-953B-A4400365AFD4Q37400355-A2A186B5-FE2F-45E7-91D2-46CF98C16014Q37609681-ED23E90D-6A44-4771-BD2D-60D1835122E1Q38120303-ADFDFB1A-5A96-41F3-9D36-19E1CE7C2873Q38268535-84967A84-77DF-4E14-ACAF-FA549508D295Q41362011-D453C400-3FD4-4EA6-AA28-82AFA9A15362Q47954235-6FDE779D-8B4A-4436-89E8-1486411C9C6DQ48849878-71D27296-D0FF-4B30-A645-B9323B752952Q52366978-C80C603F-4A54-4532-A209-9BDEDB206865Q54372533-EA2F3C64-2D0D-4965-B787-5CE148CAA915
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bexarotene: a promising anticancer agent
@ast
Bexarotene: a promising anticancer agent
@en
Bexarotene: a promising anticancer agent
@nl
type
label
Bexarotene: a promising anticancer agent
@ast
Bexarotene: a promising anticancer agent
@en
Bexarotene: a promising anticancer agent
@nl
prefLabel
Bexarotene: a promising anticancer agent
@ast
Bexarotene: a promising anticancer agent
@en
Bexarotene: a promising anticancer agent
@nl
P2860
P1476
Bexarotene: a promising anticancer agent
@en
P2093
P2860
P2888
P304
P356
10.1007/S00280-009-1140-4
P407
P50
P577
2009-09-24T00:00:00Z
P6179
1005218135